Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus MARQIBO KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus MARQIBO KIT.
FOLOTYN vs MARQIBO KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent